| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Clinical Ovarian … & Other Gynecologic Cancer Too!
|
Allen, David M.
|
|
2011
|
4 |
2 |
p. 53-
1 p.
|
article
|
| 2 |
CON: Not All Patients With Endometrial Cancer With Extrauterine Disease Should Receive Chemotherapy After Any Indicated Surgery
|
Randall, Marcus E.
|
|
2011
|
4 |
2 |
p. 66-69
4 p.
|
article
|
| 3 |
CON: Not All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment
|
Eisenhauer, Eric L.
|
|
2011
|
4 |
2 |
p. 111-113
3 p.
|
article
|
| 4 |
CON: Patients at High Risk for Ovarian Cancer Should Not Undergo Routine Screening
|
McNally, Thomas P.
|
|
2011
|
4 |
2 |
p. 86-89
4 p.
|
article
|
| 5 |
CON: Patients With Metastatic/Recurrent Cervical Cancer Should Not be Treated With Cisplatin Plus Paclitaxel
|
Thigpen, J. Tate
|
|
2011
|
4 |
2 |
p. 94-96
3 p.
|
article
|
| 6 |
CON: Patients With Recurrent Ovarian Carcinoma Should Not be Treated With Antiangiogenic Agents in Combination With Chemotherapy
|
Sabbatini, Paul
|
|
2011
|
4 |
2 |
p. 74-76
3 p.
|
article
|
| 7 |
CON: Secondary Surgical Debulking is Not an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
|
Thigpen, J. Tate
|
|
2011
|
4 |
2 |
p. 80-82
3 p.
|
article
|
| 8 |
CON: Systemic Therapy for All Endometrial Carcinomas Should Not be Paclitaxel Plus Carboplatin
|
Thigpen, J. Tate
|
|
2011
|
4 |
2 |
p. 101-105
5 p.
|
article
|
| 9 |
CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay
|
Farley, John
|
|
2011
|
4 |
2 |
p. 57-61
5 p.
|
article
|
| 10 |
Editorial Board
|
|
|
2011
|
4 |
2 |
p. A1-
1 p.
|
article
|
| 11 |
PRO: All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment
|
Boren, Todd P.
|
|
2011
|
4 |
2 |
p. 106-110
5 p.
|
article
|
| 12 |
PRO: Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening
|
Karlan, Beth Y.
|
|
2011
|
4 |
2 |
p. 83-85
3 p.
|
article
|
| 13 |
PRO: Patients With Endometrial Carcinoma Involving Extrauterine Disease Should, After Any Indicated Surgery, Receive Chemotherapy
|
Thigpen, J. Tate
|
|
2011
|
4 |
2 |
p. 62-65
4 p.
|
article
|
| 14 |
PRO: Patients With Metastatic/Recurrent Cervical Cancer Should be Treated With Cisplatin Plus Paclitaxel
|
Tewari, Krishnansu S.
|
|
2011
|
4 |
2 |
p. 90-93
4 p.
|
article
|
| 15 |
PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy
|
Boruta, David
|
|
2011
|
4 |
2 |
p. 70-73
4 p.
|
article
|
| 16 |
PRO: Secondary Surgical Debulking is an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
|
Nagel, Christa I.
|
|
2011
|
4 |
2 |
p. 77-79
3 p.
|
article
|
| 17 |
PRO: Systemic Therapy for All Endometrial Cancers Should be Paclitaxel Plus Carboplatin
|
Powell, Matthew A.
|
|
2011
|
4 |
2 |
p. 97-100
4 p.
|
article
|
| 18 |
PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay
|
Thigpen, J. Tate
|
|
2011
|
4 |
2 |
p. 54-56
3 p.
|
article
|
| 19 |
Table of Contents
|
|
|
2011
|
4 |
2 |
p. A2-A3
nvt p.
|
article
|
Journal description